TMEM87a/Elkin1, a component of a novel mechanoelectrical transduction pathway, modulates melanoma adhesion and migration

  1. Amrutha Patkunarajah
  2. Jeffrey H Stear
  3. Mirko Moroni
  4. Lioba Schroeter
  5. Jedrzej Blaszkiewicz
  6. Jacqueline LE Tearle
  7. Charles D Cox
  8. Carina Fuerst
  9. Oscar Sanchez-Carranza
  10. Maria del Angel Ocana Fernandez
  11. Raluca Fleischer
  12. Murat Eravci
  13. Christoph Weise
  14. Boris Martinac
  15. Maté Biro
  16. Gary R Lewin
  17. Kate Poole  Is a corresponding author
  1. University of New South Wales, Australia
  2. Max Delbruck Center for Molecular Medicine, Germany
  3. Victor Chang Cardiac Research Institute, Australia
  4. Freie Universitat Berlin, Germany
  5. EMBL Australia, Australia
  6. Max Delbrück Center for Molecular Medicine, Germany

Abstract

Mechanoelectrical transduction is a cellular signalling pathway where physical stimuli are converted into electro-chemical signals by mechanically activated ion channels. We describe here the presence of mechanically activated currents in melanoma cells that are dependent on TMEM87a, which we have renamed Elkin1. Heterologous expression of this protein in PIEZO1-deficient cells, that exhibit no baseline mechanosensitivity, is sufficient to reconstitute mechanically activated currents. Melanoma cells lacking functional Elkin1 exhibit defective mechanoelectrical transduction, decreased motility and increased dissociation from organotypic spheroids. By analysing cell adhesion properties, we demonstrate that Elkin1 deletion is associated with increased cell-substrate adhesion and decreased homotypic cell-cell adhesion strength. We therefore conclude that Elkin1 supports a PIEZO1-independent mechanoelectrical transduction pathway and modulates cellular adhesions and regulates melanoma cell migration and cell-cell interactions.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data file has been provided for figures 1, 3, 4, 6, 7, 8. Proteomics data provided as supplementary table 1

Article and author information

Author details

  1. Amrutha Patkunarajah

    School of Medical Sciences, University of New South Wales, Sydney, Australia
    Competing interests
    The authors declare that no competing interests exist.
  2. Jeffrey H Stear

    School of Medical Sciences, University of New South Wales, Sydney, Australia
    Competing interests
    The authors declare that no competing interests exist.
  3. Mirko Moroni

    Department of Neuroscience, Max Delbruck Center for Molecular Medicine, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Lioba Schroeter

    School of Medical Sciences, University of New South Wales, Sydney, Australia
    Competing interests
    The authors declare that no competing interests exist.
  5. Jedrzej Blaszkiewicz

    Department of Neuroscience, Max Delbruck Center for Molecular Medicine, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Jacqueline LE Tearle

    School of Medical Sciences, University of New South Wales, Sydney, Australia
    Competing interests
    The authors declare that no competing interests exist.
  7. Charles D Cox

    Molecular Cardiology and Biophysics, Victor Chang Cardiac Research Institute, Sydney, Australia
    Competing interests
    The authors declare that no competing interests exist.
  8. Carina Fuerst

    Department of Neuroscience, Max Delbruck Center for Molecular Medicine, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Oscar Sanchez-Carranza

    Department of Neuroscience, Max Delbruck Center for Molecular Medicine, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Maria del Angel Ocana Fernandez

    Department of Neuroscience, Max Delbruck Center for Molecular Medicine, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  11. Raluca Fleischer

    Department of Neuroscience, Max Delbruck Center for Molecular Medicine, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  12. Murat Eravci

    Institute of Chemistry and Biochemistry, Freie Universitat Berlin, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  13. Christoph Weise

    Institute of Chemistry and Biochemistry, Freie Universitat Berlin, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  14. Boris Martinac

    Molecular Cardiology and Biophysics, Victor Chang Cardiac Research Institute, Sydney, Australia
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8422-7082
  15. Maté Biro

    Single Molecule Science node, School of Medical Sciences, EMBL Australia, Sydney, Australia
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5852-3726
  16. Gary R Lewin

    Neuroscience, Max Delbrück Center for Molecular Medicine, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2890-6352
  17. Kate Poole

    School of Medical Sciences, University of New South Wales, Sydney, Australia
    For correspondence
    k.poole@unsw.edu.au
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0879-6093

Funding

National Health and Medical Research Council (APP1138595)

  • Boris Martinac
  • Maté Biro
  • Kate Poole

Deutsche Forschungsgemeinschaft (SFB958,project A09)

  • Gary R Lewin
  • Kate Poole

National Health and Medical Research Council (APP1135974)

  • Boris Martinac

Deutsche Forschungsgemeinschaft (SFB958,project Z03)

  • Murat Eravci
  • Christoph Weise

Humboldt Foundation (Postdoctoral Fellowship)

  • Mirko Moroni

Max Delbruck Center (Cecile Vogt Fellowship)

  • Kate Poole

Department of Education, Australian Government (RTP scholarship)

  • Amrutha Patkunarajah

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Patkunarajah et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,712
    views
  • 711
    downloads
  • 52
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Amrutha Patkunarajah
  2. Jeffrey H Stear
  3. Mirko Moroni
  4. Lioba Schroeter
  5. Jedrzej Blaszkiewicz
  6. Jacqueline LE Tearle
  7. Charles D Cox
  8. Carina Fuerst
  9. Oscar Sanchez-Carranza
  10. Maria del Angel Ocana Fernandez
  11. Raluca Fleischer
  12. Murat Eravci
  13. Christoph Weise
  14. Boris Martinac
  15. Maté Biro
  16. Gary R Lewin
  17. Kate Poole
(2020)
TMEM87a/Elkin1, a component of a novel mechanoelectrical transduction pathway, modulates melanoma adhesion and migration
eLife 9:e53308.
https://doi.org/10.7554/eLife.53308

Share this article

https://doi.org/10.7554/eLife.53308

Further reading

    1. Cancer Biology
    Ke Ning, Yuanyuan Xie ... Ling Yu
    Research Article

    For traditional laboratory microscopy observation, the multi-dimensional, real-time, in situ observation of three-dimensional (3D) tumor spheroids has always been the pain point in cell spheroid observation. In this study, we designed a side-view observation petri dish/device that reflects light, enabling in situ observation of the 3D morphology of cell spheroids using conventional inverted laboratory microscopes. We used a 3D-printed handle and frame to support a first-surface mirror, positioning the device within a cell culture petri dish to image cell spheroid samples. The imaging conditions, such as the distance between the mirror and the 3D spheroids, the light source, and the impact of the culture medium, were systematically studied to validate the in situ side-view observation. The results proved that placing the surface mirror adjacent to the spheroids enables non-destructive in situ real-time tracking of tumor spheroid formation, migration, and fusion dynamics. The correlation between spheroid thickness and dark core appearance under light microscopy and the therapeutic effects of chemotherapy doxorubicin and natural killer cells on spheroids’ 3D structure was investigated.

    1. Cancer Biology
    Ismail M Meraz, Mourad Majidi ... Jack A Roth
    Research Article

    Expression of NPRL2/TUSC4, a tumor-suppressor gene, is reduced in many cancers including NSCLC. Restoration of NPRL2 induces DNA damage, apoptosis, and cell-cycle arrest. We investigated NPRL2 antitumor immune responses in aPD1R/KRAS/STK11mt NSCLC in humanized-mice. Humanized-mice were generated by transplanting fresh human cord blood-derived CD34 stem cells into sub-lethally irradiated NSG mice. Lung-metastases were developed from KRAS/STK11mt/aPD1R A549 cells and treated with NPRL2 w/wo pembrolizumab. NPRL2-treatment reduced lung metastases significantly, whereas pembrolizumab was ineffective. Antitumor effect was greater in humanized than non-humanized-mice. NPRL2 + pembrolizumab was not synergistic in KRAS/STK11mt/aPD1R tumors but was synergistic in KRASwt/aPD1S H1299. NPRL2 also showed a significant antitumor effect on KRASmt/aPD1R LLC2 syngeneic-tumors. The antitumor effect was correlated with increased infiltration of human cytotoxic-T, HLA-DR+DC, CD11c+DC, and downregulation of myeloid and regulatory-T cells in TME. Antitumor effect was abolished upon in-vivo depletion of CD8-T, macrophages, and CD4-T cells whereas remained unaffected upon NK-cell depletion. A distinctive protein-expression profile was found after NPRL2 treatment. IFNγ, CD8b, and TBX21 associated with T-cell functions were significantly increased, whereas FOXP3, TGFB1/B2, and IL-10RA were strongly inhibited by NPRL2. A list of T-cell co-inhibitory molecules was also downregulated. Restoration of NPRL2 exhibited significantly slower tumor growth in humanized-mice, which was associated with increased presence of human cytotoxic-T, and DC and decreased percentage of Treg, MDSC, and TAM in TME. NPRL2-stable cells showed a substantial increase in colony-formation inhibition and heightened sensitivity to carboplatin. Stable-expression of NPRL2 resulted in the downregulation of MAPK and AKT-mTOR signaling. Taken-together, NPRL2 gene-therapy induces antitumor activity on KRAS/STK11mt/aPD1R tumors through DC-mediated antigen-presentation and cytotoxic immune-cell activation.